Funding
Series A+ · Biotech

Degron Therapeutics raises $40M Series A+ financing

Degron Therapeutics raised $40 million in Series A+ financing announced in May.

Updated Oct 16, 2026By RoundOS Funding desk

LAPAM Capital, GTJA Investment Group, Fortune Capital, CSPC & Growth, ApicHope, GF Xinde, CASSTAR, Kinghall Ventures and GAGE Capital are among its backers.

The company develops molecular-glue degrader medicines targeting proteins that are difficult to address with existing drugs.

Funding history

Series A+ · This round$40M

Sources

  1. Degron Therapeuticsprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related